Standard BioTools Inc. Impairment of Intangible Assets (Excluding Goodwill)
Standard BioTools Inc. (LAB) had Impairment of Intangible Assets (Excluding Goodwill) of $0 as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2022-11-09
- 2022-09-30: Impairment of Intangible Assets (Excluding Goodwill) $0.00.
- 2022-08-31: Impairment of Intangible Assets (Excluding Goodwill) $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-08-31 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |